



January 7, 2021

William Shrank, MD, MSHS
Chief Medical Officer
Humana, Inc.
500 W Main Street
Louisville, KY 40202

Dear Dr. Shrank:

I am writing on behalf of NorCal CarciNET Community, a patient organization representing those with Neuroendocrine Tumors (NETS), to request reversal of Humana's recent policy decision [Policy Number: HCS-0506-010] to refuse coverage for hybrid PET/CT and SPECT/CT procedures on the basis that they are "experimental/ investigational" and "not identified as widely used and generally accepted for the proposed uses as reported in nationally recognized peer-reviewed medical literature."

Numerous clinical studies have demonstrated the effectiveness of these hybrid procedures in managing and confirming therapy appropriateness for those with NETS. Their use has been accepted by the American Medical Association, the Centers for Medicare & Medicaid Services, guidelines by the NCCN and North American Neuroendocrine Tumor Society (NANETS). These procedures have been covered by numerous insurance providers.

Imaging using hybrid PET/CT and SPECT/CT is vital in the diagnosis and management in patient care. Accurate imaging helps avoid unnecessary and inappropriate treatments, saving both the patient and the payer time and money. It provides peace of mind, helps ensure proper treatment pathways, and in many cases saves lives.

We ask you to reverse this coverage decision and continue providing coverage for these critical scans.

Respectfully,

Josh Mailman
President
NorCal CarciNET Community